RESCINDED: FDA yanks Amarin ANCHOR SPA; shares tumble

Shares of Amarin fell 16% in after-hours trading on 29 October after it revealed the US FDA has rescinded the special protocol assessment (SPA) agreement for the company's placebo-controlled Phase III ANCHOR study of Vascepa (icosapent ethyl) – making it even more unlikely the firm will win an expanded indication for the fish oil pill.

Shares of Amarin fell 16% in after-hours trading on 29 October after it revealed the US FDA has rescinded the special protocol assessment (SPA) agreement for the company's placebo-controlled Phase III ANCHOR study of Vascepa (icosapent ethyl) – making it even more unlikely the firm will win an expanded indication for the fish oil pill.

Vascepa, a semisynthetic, 96% ultra-pure ethyl ester of eicosapentaenoic acid, already is approved as an adjunct to diet to reduce...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip